EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RNA Polymerase 1 inhibitors against African trypanosomes in vitro and in mice

Alexander V Cumming iD, Nathaniel P Nenortas, Elizabeth Nenortas, Rahul P Bakshi, Emily R Caton, Estefany Rios-Guzman, Mary E Barry, James C Barrow, Marikki Laiho, Theresa A Shapiro iD

Antimicrobial Agents and Chemotherapy · 06.05.2026 · 70 (5)

DOI: 10.1128/aac.01492-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.05.2026. Verfasst von Alexander V Cumming und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Trypanosoma brucei brucei, Trypanosomiasis, African, RNA Polymerase I, Trypanocidal Agents. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapy of human African trypanosomiasis, fatal if not treated, has been greatly improved by orally available and safer fexinidazole, but reliable cure of late-stage central nervous system (CNS) infection remains a challenge. African trypanosomes are unique among eukaryotes in having an RNA Polymerase 1 that transcribes not only rRNA but also mRNA that encodes the abundant variable surface glycoprotein (VSG) that coats the cell membrane of bloodstream-form parasites and allows them to evade host immune defenses. RNA Pol 1 inhibitor BMH-21, an intercalator not associated with DNA damage and a lead for new cancer therapy, has reported activity against the synthesis of rRNA and VSG mRNA in Trypanosoma brucei brucei . We evaluated a library of BMH-21 analogs against bloodstream-form T. b. brucei in vitro and found limited tolerance for structural modification. Striking and time-dependent bimodal dose-response curves indicate these compounds have a complex mechanism of action. Most potent against T. b. brucei was benzopyridoquinazoline Compound 2 , with an EC 50 of 84 nM. Analysis of in vitro pharmacokinetic-pharmacodynamic (PK-PD) relationships by a hollow fiber model system revealed that in T. b. brucei , the kinetic driver of Compound 2 is drug concentration, a finding that was confirmed by dose fractionation in infected mice and that highlights the utility of the in vitro system for assessing antitrypanosomal PK-PD. Although Compound 2 accumulates 20-fold in mouse brain tissue vs plasma, efficacy against CNS T. b. brucei in mice was limited. RNA Pol 1 remains an attractive target for developing new and more selectively toxic antitrypanosomal agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanosoma brucei bruceiTrypanosomiasis, AfricanRNA Polymerase ITrypanocidal AgentsQuinazolinesEnzyme InhibitorsAnimalsMiceFemale

Stichwörter der Autor:innen

BMH-21BOB-42LI-623PK-PDRNA Polymerase 1Trypanosoma brucei bruceihollow fiber model systeminhibitorstrypanosomiasis

Substanzen

RNA Polymerase ITrypanocidal AgentsQuinazolinesEnzyme Inhibitors

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Pharmacology, Lieber Institute for Brain Development, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Physiology, Pharmacology and Therapeutics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Alexander V Cumming, Theresa A Shapiro

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • Lieber Institute for Brain Development
  • Blue One Biosciences LLC
  • National Institutes of Health

Zitieren

APA

Cumming, A. V., Nenortas, N. P., Nenortas, E., Bakshi, R. P., Caton, E. R., Rios-Guzman, E., Barry, M. E., Barrow, J. C., Laiho, M., & Shapiro, T. A. (2026). RNA Polymerase 1 inhibitors against African trypanosomes in vitro and in mice. Antimicrobial Agents and Chemotherapy, 70(5). https://doi.org/10.1128/aac.01492-25

Vancouver

Cumming AV, Nenortas NP, Nenortas E, Bakshi RP, Caton ER, Rios-Guzman E, et al. RNA Polymerase 1 inhibitors against African trypanosomes in vitro and in mice. Antimicrobial Agents and Chemotherapy. 2026;70(5). doi:10.1128/aac.01492-25

BibTeX
@article{Cumming2026,
  author = {Cumming, Alexander V and Nenortas, Nathaniel P and Nenortas, Elizabeth and Bakshi, Rahul P and Caton, Emily R and Rios-Guzman, Estefany and Barry, Mary E and Barrow, James C and Laiho, Marikki and Shapiro, Theresa A},
  title = {RNA Polymerase 1 inhibitors against African trypanosomes in vitro and in mice},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {5},
  doi = {10.1128/aac.01492-25}
}
Kostenlos starten →